DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer
DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer
Recruiting · NCT06313086 · Registry updated 2024-05-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer | HER2-positive Breast Cancer | Recruiting | Phase 3 | 2024-05-10 | NCT06313086 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 39 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Fudan University Shanghai Cancer Center | Shanghai | China | 257 |